Last reviewed · How we verify
Indomethacin ophthalmic solution
At a glance
| Generic name | Indomethacin ophthalmic solution |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
- Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC (PHASE1, PHASE2)
- Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3% (EARLY_PHASE1)
- Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT (PHASE4)
- Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 (PHASE3)
- Efficacy Study of Ketorolac and HPMC to Treat Dry Eye (PHASE2)
- S.L. Spray Solution® and Difflam® and Acular®Spray for the Prevention of Postoperative Sore Throat (PHASE4)
- Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Indomethacin ophthalmic solution CI brief — competitive landscape report
- Indomethacin ophthalmic solution updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI